Read all about it! The latest news from the medical technology experts

Ingeneus launches IOPvet device

Further patents issued in key regions for the eyePressure device

Revolutionising high eyePressure detection around Australia - and even in the Antarctic

Patents issued in key regions for the eyeTelehealth Platform

Patent issued for Ingeneus' eyeConnect device in China

Patents issued in the US and China for eyeTelehealth products

World first eyeConnect unveiled at Frankston Hospital

Ingeneus products - Good Design Awards winners

Ingeneus products in Good Design Awards finals

Ingeneus appoints new GM Manufacturing

Ingeneus launches eyePressure device

Ingeneus works with SMART Arm

Ingeneus achieves CE Marking for ophthalmic system

Ingeneus on the move

Ingeneus develops new remote diagnostic tool

Ingeneus wins TGA and CE manufacturing approval for cataract surgery device

Medical device treats Ocular Pathologies during Vitreoretinal Surgery

V-Patch Medical Systems: reaching the hearts of the travelling public

Double Success for Ingeneus in Government Program

Ingeneus advocates change to the Therapeutic Goods Administration (TGA)

Ingeneus Exhibits at AusMedtech 2011 Conference

Dynamic enhancement of Ingeneus QMS for medical devices and biomedical applications

Exciting opportunities at BiOS 2011 for Ingeneus

Ingeneus engages with emerging markets

New branding & website under Design Vic Business Immersion program

Ingeneus completes software training with its clients

Ingeneus passes TGA Surveillance Audit

Ingeneus signs licensing agreement for low cost diabetic retinopathy system

Ingeneus launches eyePressure device


Ingeneus achieves CE Marking for ophthalmic system

3rd September 2013

Ingeneus is pleased to announce that it has achieved CE Marking for its low cost treatment system for diabetic retinopathy, an eye disease that affects many diabetics. The system was developed by Ingeneus for use by ophthalmic clinicians.

CE Marking signifies that the product complies with the essential health, safety and environmental protection requirements of the European Medical Device Directive.

Ingeneus CEO Richard Walmsley said, “We are excited to receive the CE Mark as it means the system can be used by ophthalmic clinicians throughout Europe. It assures surgeons and patients of the safety and efficacy of our device.

The system provides clinicians with a complete laser solution in the treatment of ocular pathology and provides a new level of performance compared with existing surgery systems,” Richard said.

“It is used in photocoagulation of both anterior and posterior segments of the eye including retinal photocoagulation.”